Jiahui Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiahui Lu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Yongming Zhou
Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, China
2 shared publications - Huili Sun
Bao Zhong Tang TCM Center, Blk 5 Level 1, Singapore General Hospital, Outram Road, Singapore 169608, Singapore
1 shared publication - Jue Sun
Bao Zhong Tang TCM Center, Blk 5 Level 1, Singapore General Hospital, Outram Road, Singapore 169608, Singapore
1 shared publication - Lay-Cheng Lim
Department of Haematology, Blk 6 Level 5, Singapore General Hospital, Outram Road, Singapore 169608, Singapore
1 shared publication Xue-Li Wei
1 shared publication- Yeh Ching Linn
Department of Haematology, Singapore General Hospital, Singapore
1 shared publication
Latest Publications
- 31 August 2011
- Published by Elsevier in Complementary Therapies in Clinical Practice
- Vol. 17 (3) , 152-156
Traditional Chinese herbal medicine in the supportive management of patients with chronic cytopaenic marrow diseases – A phase I/II clinical study
- 31 August 2011
- Published by Elsevier in Complementary Therapies in Clinical Practice
- Vol. 17 (3) , 152-156
Traditional Chinese herbal medicine in the supportive management of patients with chronic cytopaenic marrow diseases – A phase I/II clinical study
- 1 November 2006
- Vol. 26 (11) , 973-7
[Changes in T-cell receptor repertoire in aplastic anemia and effects of Shengxue Mixture].
To explore the immune pathogenesis of aplastic anemia (AA) and the therapeutic effects of Shengxue Mixture (SM) through the gene expressions of subfamilies of T-cell receptor variable region beta (TCR Vbeta) using immunologic and molecular biologic technology. Gene expressions of TCR Vbeta sub-families in peripheral blood mononuclear cells from 20 AA patients were detected before and after treatment with SM using RT-PCR and gene scanning method. TCR Vbeta gene repertoire of the 24 subfamily genes deviated in AA patients, and the oligoclonal gene expressions increased obviously compared with those in healthy people (P < 0.01), including Vbeta2, 5, 6, 15, 16, 22, and 23 were found in 30%-50% AA patients, and Vbeta8, 21 were in more than 50% patients. These oligoclonal genes reduced significantly after treatment with SM compared with those before treatment (P < 0.05). Multiple TCR Vbeta subfamilies of clonal proliferation participate in the pathogenesis of AA. SM can rectify the deviation of TCR Vbeta gene repertoire, reduce the abnormal clonal proliferation of T cells, thus to alleviate the immune injury to hematopoietic tissue, and thus to benefit the recovery of hematopoiesis of bone marrow.
- 1 November 2006
- Vol. 26 (11) , 973-7
[Changes in T-cell receptor repertoire in aplastic anemia and effects of Shengxue Mixture].
To explore the immune pathogenesis of aplastic anemia (AA) and the therapeutic effects of Shengxue Mixture (SM) through the gene expressions of subfamilies of T-cell receptor variable region beta (TCR Vbeta) using immunologic and molecular biologic technology. Gene expressions of TCR Vbeta sub-families in peripheral blood mononuclear cells from 20 AA patients were detected before and after treatment with SM using RT-PCR and gene scanning method. TCR Vbeta gene repertoire of the 24 subfamily genes deviated in AA patients, and the oligoclonal gene expressions increased obviously compared with those in healthy people (P < 0.01), including Vbeta2, 5, 6, 15, 16, 22, and 23 were found in 30%-50% AA patients, and Vbeta8, 21 were in more than 50% patients. These oligoclonal genes reduced significantly after treatment with SM compared with those before treatment (P < 0.05). Multiple TCR Vbeta subfamilies of clonal proliferation participate in the pathogenesis of AA. SM can rectify the deviation of TCR Vbeta gene repertoire, reduce the abnormal clonal proliferation of T cells, thus to alleviate the immune injury to hematopoietic tissue, and thus to benefit the recovery of hematopoiesis of bone marrow.